Daiwa Securities Group
STRO icon

Daiwa Securities Group’s Sutro Biopharma STRO Stock Holding History

Daiwa Securities Group’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-16
Closed -$1K – 1390
2023
Q3 		$1K Hold
16
– – ﹤0.01% 1276
2023
Q2 		$1K Hold
16
– – ﹤0.01% 1299
2023
Q1 		$1K Hold
16
– – ﹤0.01% 1282
2022
Q4 		$1K Hold
16
– – ﹤0.01% 1292
2022
Q3 		$1K Hold
16
– – ﹤0.01% 1315
2022
Q2 		$1K Hold
16
– – ﹤0.01% 1323
2022
Q1 		$1K Hold
16
– – ﹤0.01% 1340
2021
Q4 		$2K Hold
16
– – ﹤0.01% 1299
2021
Q3 		$3K Buy
16
+7
+78% +$1.33K ﹤0.01% 1229
2021
Q2 		$2K Hold
9
– – ﹤0.01% 1159
2021
Q1 		$2K Buy
9
+2
+29% +$475 ﹤0.01% 1163
2020
Q4 		$2K Buy
+7
New +$1.16K ﹤0.01% 1139

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Daiwa Securities Group's STRO Position: Q4 2023 in Review

Daiwa Securities Group sold out of Sutro Biopharma (STRO) in Q4 2023, closing a stake of 16 shares — an estimated $1K sold.

Daiwa Securities Group first reported a position in STRO in Q4 2020 and held it in 12 quarters. The position peaked at $3K in Q3 2021. 114 funds tracked by Wall St. Rank hold STRO as of Q4 2023.

  • Daiwa Securities Group reported no remaining Sutro Biopharma position as of Q4 2023 after selling out during the quarter.
  • Daiwa Securities Group sold 16 Sutro Biopharma shares in Q4 2023, an estimated $1K.
  • Daiwa Securities Group first reported a position in Sutro Biopharma in Q4 2020 and held it in 12 quarters.
  • Daiwa Securities Group's Sutro Biopharma position peaked at $3K in Q3 2021.
  • 114 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2023.

Based on Daiwa Securities Group's 13F filing for Q4 2023, filed 31 Jan 2024.